Urs Christen

Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the autoimmune process is already ongoing.

Discrete proteolysis of focal contact and adherens junction components in Porphyromonas gingivalis-infected oral keratinocytes: a strategy for cell adhesion and migration disabling.

Molecular anatomy of antigen-specific CD8(+) T cell engagement and synapse formation in vivo.

Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model.

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Cytokines and chemokines in virus-induced autoimmunity.

Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease.

Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient.

Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells.

Induction, acceleration or prevention of autoimmunity by molecular mimicry.

Virally induced inflammation and therapeutic avenues in type 1 diabetes.

CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors.

Initiation of autoimmunity.

IP-10 and type 1 diabetes: a question of time and location.

A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes.

Manipulating the type 1 vs type 2 balance in type 1 diabetes.

IP-10 and type 1 diabetes: a question of time and location.

Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics.

Infections and autoimmunity--good or bad?

Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development.

Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies.

SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes.

Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies.

Chemokines as drug targets in type 1 diabetes.

Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice.

Animal models for autoimmune hepatitis.

Systemic anti-TNFalpha treatment restores diabetes-impaired skin repair in ob/ob mice by inactivation of macrophages.

Viral infection--a cure for type 1 diabetes?

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection.

New animal models for autoimmune hepatitis.

Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty?

Adenovirus E3 MHC inhibitory genes but not TNF/Fas apoptotic inhibitory genes expressed in beta cells prevent autoimmune diabetes.

Enterovirus infection of human beta-cells activates dendritic cells and triggers innate antiviral responses: are enteroviruses convicted now?

Cytochrome P450 2D6 as a model antigen.

CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation.

Early production of IL-22 but not IL-17 by peripheral blood mononuclear cells exposed to live Borrelia burgdorferi: the role of monocytes and interleukin-1.

Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference?

Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.